title: Intensity-modulated radiation therapy with hypoxic sensitizer AK-2123 (sanazole) for glioblastoma multiforme using simultaneous integrated boost technique.
abstract: BACKGROUND
  Glioblastoma has a very poor prognosis even after incorporation into therapy of the newly-developed drug, temozolomide.
  
  
  METHODS
  We present a case of 62-year-old woman with glioblastoma multiforme treated with tomotherapy intensity-modulated radiation therapy using simultaneous integrated boost technique (SIB-IMRT) along with a daily oral dose of a hypoxic radiation sensitizer, sanazole (AK-2123). SIB-IMRT was administered at a dose of 60 Gy in 20 fractions for high-risk planning target volume (PTV) and at 40 Gy for low-risk PTV. The patient received an oral administration of sanazole (1.0 g/day) for 10 days, 2 h before radiotherapy. She achieved a complete response without any adverse events, and remained disease-free for 3.5 years. Our study demonstrates that the higher single-dose radiotherapy combined with a hypoxic radiation sensitizer has the potential to enhance the efficacy of radiotherapy.
authors.affiliation: Department of Radiology, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto, Japan. hideya10@hotmail.com
authors.forename: Hideya
authors.initials: H
authors.lastname: Yamazaki
authors.forename: Satoaki
authors.initials: S
authors.lastname: Nakamura
authors.forename: Takuya
authors.initials: T
authors.lastname: Nishimura
authors.forename: Haruumi
authors.initials: H
authors.lastname: Okabe
authors.forename: Norihiro
authors.initials: N
authors.lastname: Aibe
authors.forename: Ken
authors.initials: K
authors.lastname: Yoshida
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Kagiya
mesh_terms: D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D059248:Chemoradiotherapy; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy / Q000532:radiotherapy*; D006801:Humans; D000860:Hypoxia; D008875:Middle Aged; D011379:Prognosis; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D011880:Radiotherapy Planning, Computer-Assisted; D050397:Radiotherapy, Intensity-Modulated; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D011838:Radiation-Sensitizing Agents; D014230:Triazoles; C072690:AK 2123